Exercise Testing Reveals Heart Rate Unreliability in Cancer Immunotherapy Patients

Cancer patients receiving immunotherapy checkpoint inhibitors may experience cardiovascular changes that affect exercise testing reliability, according to new research comparing their responses to healthy controls during cycling exercise.

The study examined 13 cancer patients on checkpoint inhibitor therapy and 13 age-matched healthy controls during moderate-intensity cycling tests. Researchers measured oxygen uptake (VO2) and heart rate responses to assess exercise capacity and cardiovascular function.

Key findings revealed that while cancer patients reached similar maximum heart rates as controls, they showed significantly more variable heart rate responses during exercise. The coefficient of variation for heart rate was twice as high in cancer patients (24% vs 10%). In contrast, VO2 kinetics remained reliable in both groups, with good-to-excellent consistency across repeated tests.

These results suggest that traditional heart rate-based exercise prescriptions may be less accurate for cancer patients receiving immunotherapy. The increased heart rate variability could indicate early cardiovascular deconditioning, even when patients feel they're exerting similar effort levels.

For clinicians and patients, this research highlights the importance of using VO2-based rather than heart rate-based metrics when designing exercise programs for cancer patients on immunotherapy. The findings also underscore the need for more comprehensive cardiovascular monitoring in this population, as subtle changes may occur before obvious symptoms develop.